0 CHECKOUT

Global Ophthalmics Partnering 2010-2016: Deal trends, players and financials

  • ID: 2367212
  • May 2016
  • Region: Global
  • 500 Pages
  • CurrentPartnering
1 of 4

Global Ophthalmics Partnering 2010 to 2016 provides the full collection of Ophthalmics disease deals signed between the world’s pharmaceutical and biotechnology companies since 2010.

Trends in Ophthalmics partnering deals
Financial deal terms for headline, upfront and royalty by stage of development
Ophthalmics partnering agreement structure
Ophthalmics partnering contract documents
Top Ophthalmics deals by value
Most active Ophthalmics dealmakers

Most of the deals included within the report occur when a licensee obtains a right or an option right to license a licensor’s product or technology. More often these days these deals tend to be multi-component including both a collaborative R&D and a commercialization of outcomes element.

The report takes readers through the comprehensive Ophthalmics disease deal trends, key players and top deal values allowing the understanding of how, why and under what terms companies are currently entering Ophthalmics deals.

The report presents financial deal terms values for Ophthalmics deals, where available listing by overall headline values, upfront payments, milestones and royalties enabling READ MORE >

Note: Product cover images may vary from those shown
2 of 4

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Ophthalmics dealmaking

2.1. Introduction
2.2. Ophthalmics partnering over the years
2.3. Ophthalmics partnering by deal type
2.4. Ophthalmics partnering by industry sector
2.5. Ophthalmics partnering by stage of development
2.6. Ophthalmics partnering by technology type
2.7. Ophthalmics partnering by therapeutic indication

Chapter 3 -Financial deal terms for Ophthalmics partnering

3.1. Introduction
3.2. Disclosed financials terms for Ophthalmics partnering
3.3. Ophthalmics partnering headline values
3.4. Ophthalmics deal upfront payments
3.5. Ophthalmics deal milestone payments
3.6. Ophthalmics royalty rates

Chapter 4 - Leading Ophthalmics deals and dealmakers

4.1. Introduction
4.2. Most active in Ophthalmics partnering
4.3. List of most active dealmakers in Ophthalmics
4.4. Top Ophthalmics deals by value

Chapter 5 - Ophthalmics contract document directory

5.1. Introduction
5.2. Ophthalmics partnering deals where contract document available

Chapter 6 - Ophthalmics dealmaking by therapeutic target

6.1. Introduction
6.2. Deals by Ophthalmics therapeutic target

Appendices

Appendix 1 - Directory of Ophthalmics deals by company A-Z 2010 to 2016
Appendix 2 - Directory of Ophthalmics deals by deal type 2010 to 2016
Appendix 3 - Directory of Ophthalmics deals by stage of development 2010 to 2016
Appendix 4 - Directory of Ophthalmics deals by technology type 2010 to 2016
Further reading on dealmaking
Deal type definitions

About

Table of figures

Figure 1: Ophthalmics partnering since 2010
Figure 2: Ophthalmics partnering by deal type since 2010
Figure 3: Ophthalmics partnering by industry sector since 2010
Figure 4: Ophthalmics partnering by stage of development since 2010
Figure 5: Ophthalmics partnering by technology type since 2010
Figure 6: Ophthalmics partnering by indication since 2010
Figure 7: Ophthalmics deals with a headline value
Figure 8: Ophthalmics deals with upfront payment values
Figure 9: Ophthalmics deals with milestone payment
Figure 10: Ophthalmics deals with royalty rates
Figure 11: Active Ophthalmics dealmaking activity- 2010 to 2016
Figure 12: Top Ophthalmics deals by value since 2010

Note: Product cover images may vary from those shown
3 of 4

Global Ophthalmics Partnering 2010 to 2016 provides the reader with the following key benefits:

- In-depth understanding of Ophthalmics deal trends since 2010
- Access Ophthalmics deal headline, upfront, milestone and royalty data
- Research hundreds of actual contracts between Ophthalmics partner companies
- Comprehensive access to over 750 links to actual Ophthalmics deals entered into by the world’s biopharma companies
- Indepth review of Ophthalmics deals entered into by the top 25 most active dealmakers
- Benchmark the key deal terms companies have agreed in previous deals
- Identify key terms under which companies partner Ophthalmics opportunities
- Uncover companies actively partnering Ophthalmics opportunities

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be shipped to you in CD ROM format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a 1-5 user licence, allowing up to five users have access to the product.

  • Quick Help: The report will be shipped to you in CD ROM format. This is a 1-5 user licence, allowing up to five users have access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be shipped to you in CD ROM format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

  • Quick Help: A copy of the report will be emailed to you and a copy will be shipped to you in CD ROM format. The Electronic copy is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • AB Sciex
  • Eli Lilly and Company
  • B. Braun Melsungen AG
  • Astellas Pharma, Inc.
  • Hologic Inc.
  • Merck & Co., Inc.